Chan Zuckerberg Biohub NetworkHighlight
Summary
About the Role
About You
- A PhD in Bioengineering, Molecular Biology, Genetics, Immunology, or related field.
- Hands-on experience with CRISPR/Cas genome editing, perturbation screens, and enhancer assays.
- Familiarity with base and prime editing, and CRISPR off-target profiling.
- Expertise in immune cell biology, including isolation, culture, and functional assays for primary immune cells and/or HSPCs.
- Proven ability to troubleshoot complex experimental workflows and work independently.
- Track record in single-cell technology development and application.
- Prior work with 3D organoid systems or microfluidics for immune cell studies.
- Understanding of gene regulatory network modeling and enhancer-promoter interaction mapping (Hi-C, HiChIP).
Benefits
- Generous employer match on employee 401(k) contributions.
- Paid time off to volunteer at an organization of your choice.
- Funding for select family-forming benefits.
- Relocation support for employees who need assistance moving.
The Chan Zuckerberg Biohub Network is a group of nonprofit research institutes that bring together scientists, engineers, and physicians with the goal of pursuing grand scientific challenges on 10- to 15-year time horizons. The CZ Biohub Network focuses on understanding underlying mechanisms of disease and developing new technologies that will lead to actionable diagnostics and effective therapies. CZ Biohub San Francisco — which was the inaugural Biohub and launched in 2016 — works on elucidating dynamic cell systems across scales in health and disease, joining forces with the Bay Area’s leading academic institutions — Stanford University, UC Berkeley, and UC San Francisco — to do bold, visionary science that can’t be done elsewhere. CZ Biohub Chicago, which launched in 2023, focuses on engineering technologies to make precise, molecular-level measurements of biological processes within human tissues, with an ultimate goal of understanding and treating the inflammatory states that underlie many diseases. It catalyzes collaboration between the University of Chicago, Northwestern University, and the University of Illinois Urbana-Champaign. CZ Biohub New York, which launched in 2023, brings together Columbia University, The Rockefeller University, and Yale University to bioengineer immune cells to sense and record signals of disease and adapt these cells to spot diseases such as lethal cancers and Alzheimer’s in their earliest stages, long before they are usually diagnosed.